Abstracts tagged "Biomarkers"

Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2677 • 2015 ACR/ARHP Annual Meeting
Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in Patients with Rheumatoid Arthritis
Ankita Satpute¹, Stanley Hazen^2,3, WH Wilson Tang³ and M. Elaine Husni⁴, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Cell Biology, Cell Biology, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiology, Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Numerous studies have reported increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA) patients that cannot be explained by traditional risk factors. In a…
Abstract Number: 3108 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives
Carol Hitchon¹, Irene Smolik², Xiaobo Meng¹, David Robinson² and Hani S. El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Indigenous North Americans (INA) have high prevalence rates of severe erosive rheumatoid arthritis (RA). We have established a cohort of unaffected first degree relatives…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 770 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Alfred Kim¹, Vibeke Strand², Nancy Mathis¹, Deepali Sen³, Jonathan Miner³, Elizabeth Schramm¹, Robin Bruchas⁴, Nick Staten⁴, Paul Olson⁴, Chad Stiening⁴ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1243 • 2015 ACR/ARHP Annual Meeting
Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis
Seiji Nakamura¹, Hiroshi Iijima¹, Yuko Hata², Yohei Ishizawa², Chun Ren Lim², Ryo Matoba², Katsuya Suzuki³, Koichi Amano⁴ and Tsutomu Takeuchi³, ¹Kanagawa, DNA Chip Research Inc., Yokohama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Employing genome-wide gene transcription on a unified platform, to identify molecular signatures for predicting therapeutic effects for rheumatoid arthritis (RA) with three biologics, infliximab…
Abstract Number: 1742 • 2015 ACR/ARHP Annual Meeting
Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity
Natasja Stæhr Gudman¹, Anne Friesgaard Christensen², Grith Lykke Sørensen³, Anne C. Bay-Jensen⁴, Anne Sofie Siebuhr⁵, Morten Asser Karsdal⁶, Heidi Lausten Munk⁷, Leif Ejstrup⁸, Anne Gitte Loft⁹ and Peter Junker¹⁰, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark, ³Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark, ⁴Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁶Research & Development, Nordic Bioscience, Herlev, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Odense University Hosp, SDR Blvd, Odense, Denmark, ⁹Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ¹⁰University of Southern Denmark, Odense, Denmark
Background/Purpose: AxSpA and PsA are core members of the spondyloarthritis complex. One cardinal characteristic shared by these two conditions is increased remodeling of bone and…
Abstract Number: 2066 • 2015 ACR/ARHP Annual Meeting
Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Melissa E. Munroe¹, Evan G. Vista², Joan T. Merrill³, Joel M. Guthridge¹, Virginia C. Roberts¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted disease characterized by immune dysregulation and varied disease activity. Identifying mechanistic mediators of altered disease activity would help prevent damage…
Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Zuzana Tatar¹, Carole Migne², Mélanie Petera³, Estelle Pujos Guillot⁴, Philippe Gaudin^5,6, T Lequerré⁷, Hubert Marotte⁸, Jacques Tebib⁹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, ³Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, ⁴Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, ⁵Rheumatology, University Hospital, Grenoble, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, ⁸INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ⁹Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Zoltan Konthur¹, Ute Nonhof², Melvin Michael Wiemkes³, Jacqueline Detert³, Tanja Braun⁴, Jörg Hollidt², Gerd Burmester⁵ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 1259 • 2015 ACR/ARHP Annual Meeting
Verification of Haptoglobin and Von Willebrand Factor As Potential Biomarkers of Knee Osteoarthritis Using a Targeted Proteomics Approach in Serum
Patricia Fernandez-Puente¹, Valentina Calamia¹, Jesús Mateos¹, Lucia Lourido¹, Beatriz Rocha², Cristina Ruiz-Romero¹ and Francisco J. Blanco¹, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: The current diagnosis of osteoarthritis (OA) relies on the description of pain symptoms, affected joint stiffness, and radiography used as the reference technique…
Abstract Number: 1846 • 2015 ACR/ARHP Annual Meeting
IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis
Huihua Ding¹, Chandra Mohan¹ and Tianfu Wu², ¹Biomedical Engineering, University of Houston, Houston, TX, ²Department of Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the golden standard for the diagnosis…
Abstract Number: 2122 • 2015 ACR/ARHP Annual Meeting
A Novel Severity Score Based on Cardiac Neonatal Lupus Manifestations Serves As a Predictor and Outcome Measure of Morbidity in Anti-Ro Exposed Fetuses
Amit Saxena¹, Peter M. Izmirly¹, Sung Won Han², Paraskevi Briassouli¹, Tania Rivera³, Mark Halushka⁴, Hua Zhong⁵, Deborah Friedman⁶, Robert Clancy¹ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, New York University School of Medicine, New York, NY, ³Rheumatology, Scripps Memorial Hospital La Jolla, La Jolla, CA, ⁴Division of Cardiovascular Pathology, John Hopkins Pathology, Baltmore, MD, ⁵Population Health, New York University School of Medicine, New York, NY, ⁶Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro face a spectrum of fetal consequences when pregnant, from complete wellbeing to death from cardiac neonatal lupus (cardiac NL). Transplacental passage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].